FAQ/Help |
Calendar |
Search |
Today's Posts |
06-14-2015, 08:57 PM | #1 | ||
|
|||
Member
|
NTCELL® Clinical Study in Parkinson’s Meets Endpoints
Living Cell Technologies Advancing Regenerative Cell Therapy into Larger Phase IIb Study to Evaluate Its Potential as a Disease-modifying Treatment Company to Host Conference Call on Thursday 18 June at 8:30 a.m. AEST / 10:30 a.m. NZT The Phase I/IIa clinical study of NTCELL®, conducted in four patients in New Zealand, met its primary endpoint of safety, showing NTCELL implantation was well tolerated, with no adverse events considered to be related to NTCELL. NTCELL implantation also improved clinical features of Parkinson’s disease in the four patients studied, as measured by validated neurological rating scales and questionnaires, with the improvement sustained at 26 weeks post-implant. LCT plans to initiate the confirmatory Phase IIb study in the fourth quarter of 2015. The study will be led by Dr. Snow at Auckland City Hospital. The efficacy and safety endpoints will be the same as those evaluated in the Phase I/IIa study. |
||
Reply With Quote |
06-14-2015, 08:59 PM | #2 | ||
|
|||
Member
|
|
||
Reply With Quote |
06-14-2015, 11:00 PM | #3 | ||
|
|||
Member
|
|
||
Reply With Quote |
06-15-2015, 07:53 AM | #4 | ||
|
|||
Magnate
|
|
||
Reply With Quote |
06-15-2015, 12:26 PM | #5 | ||
|
|||
Member
|
Quote:
As such it failed. Perhaps this is different. Neil. |
||
Reply With Quote |
06-15-2015, 01:23 PM | #6 | ||
|
|||
Magnate
|
Quote:
LCT cells are from pigs that were dropped off on a remote island years ago and are uniquely isolated from pig and other diseases. |
||
Reply With Quote |
06-15-2015, 01:23 PM | #7 | ||
|
|||
Member
|
Quote:
https://www.michaeljfox.org/foundati...=76&category=3 |
||
Reply With Quote |
06-15-2015, 01:29 PM | #8 | ||
|
|||
Member
|
kiwi33 this is in your neck of the woods?
|
||
Reply With Quote |
06-16-2015, 04:19 PM | #9 | |||
|
||||
Member
|
My neck of the woods too
Very small trial totally NZ initiated and driven. Arose from NZ research. I imagine it will be 3 plus years before we really know how it's going. The positive is no rejection of the implant. Novel to use pig cells and the presence of cerebrospinal fluid is a first I think. Kiwi waiting to hear your take on it (and I was amused by this mistake in the U.S. NIH specs - ability to fly to Vancouver for PET scan - 10 plus hours, really!)
__________________
"We don't see things as they are, we see them as we are." Anais Nin. |
|||
Reply With Quote |
"Thanks for this!" says: | Tupelo3 (06-17-2015) |
06-16-2015, 05:05 PM | #10 | ||
|
|||
Member
|
Do you know a fellow parky who posted on this site as rationalist and Howardh.
Real positive guy often wondered what happened to him. Anyway back to the thread. Neil. |
||
Reply With Quote |
Reply |
|
|
Similar Threads | ||||
Thread | Forum | |||
NTCELL LCT Parkinson’s trial resumes patient recruitment | Parkinson's Disease | |||
Successful second implant of NTCELL for Parkinson's disease | Parkinson's Disease | |||
1st patientPhase I clinical trial of the regenerative cell therapy NTCELL - pig cells | Parkinson's Disease | |||
Biotie's tozadenant (SYN115) meets primary and multiple secondary endpoints in phase | Parkinson's Disease | |||
Spheramine(r) phase IIB study did not meet endpoints | Parkinson's Disease Clinical Trials |